Title : Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.

Pub. Date : 2004

PMID : 14560062






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients with AD + CVD treated with galantamine experienced statistically and clinically significant improvement in cognition at month 6 (mean change in ADAS-cog/11 score -1.1; p < or = 0.05 vs. baseline) and maintained their cognitive function for the entire 12-month study (mean change in ADAS-cog/11 score +0.1). Galantamine alkylglycerone phosphate synthase Homo sapiens
2 Patients with AD + CVD treated with galantamine experienced statistically and clinically significant improvement in cognition at month 6 (mean change in ADAS-cog/11 score -1.1; p < or = 0.05 vs. baseline) and maintained their cognitive function for the entire 12-month study (mean change in ADAS-cog/11 score +0.1). Galantamine alkylglycerone phosphate synthase Homo sapiens